Tardive dyskinesia can affect many areas of your life, including your social life and self-confidence. Learning how to manage these effects can help improve your overall well-being and daily ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

The drug treats tardive dyskinesia, a disorder characterized by involuntary facial and body movements, and chorea associated with Huntington's disease. The company also has an extensive pipeline ...

After suffering from a long battle with Tardive Dyskinesia and Parkinsons Disease Glenn R. Buddy Clark, age 69, passed away at the South Mountain Restoration Center on Sunday, February 16 ...